| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1016969441 |
| P356 | DOI | 10.1038/BONEKEY.2014.14 |
| P8608 | Fatcat ID | release_oapyafxtnndsfgccnezlujgz4q |
| P3181 | OpenCitations bibliographic resource ID | 2733696 |
| P932 | PMC publication ID | 4007167 |
| P698 | PubMed publication ID | 24795813 |
| P5875 | ResearchGate publication ID | 262055837 |
| P50 | author | Eva Gonzalez-Suarez | Q56480850 |
| P2093 | author name string | William C Dougall | |
| Ingunn Holen | |||
| P2860 | cites work | Progestin effects on cell proliferation pathways in the postmenopausal mammary gland | Q21092903 |
| Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 | ||
| Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 | ||
| RANK is essential for osteoclast and lymph node development | Q24598872 | ||
| Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer | Q24605866 | ||
| The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development | Q28142247 | ||
| Relationship between serum RANKL and RANKL in bone | Q28245828 | ||
| Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab | Q28265584 | ||
| Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials | Q28275006 | ||
| Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin | Q28294196 | ||
| RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis | Q28294501 | ||
| OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 | ||
| Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients | Q28740575 | ||
| Metastasis to bone: causes, consequences and therapeutic opportunities | Q29614310 | ||
| RANKL/RANK/MMP-1 molecular triad contributes to the metastatic phenotype of breast and prostate cancer cells in vitro | Q30419245 | ||
| Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases | Q33293423 | ||
| Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. | Q33733718 | ||
| Progesterone induces adult mammary stem cell expansion | Q42471079 | ||
| Significance of the fibrous stroma in bone invasion by human gingival squamous cell carcinomas | Q42811261 | ||
| Control of mammary stem cell function by steroid hormone signalling. | Q43103606 | ||
| The evolving systemic and local biomarker milieu at different stages of disease progression in rat adjuvant-induced arthritis | Q43494262 | ||
| Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis | Q44486779 | ||
| Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases | Q45814967 | ||
| In vivo real-time imaging of TGF-beta-induced transcriptional activation of the RANK ligand gene promoter in intraosseous prostate cancer | Q47816427 | ||
| Progesterone/RANKL is a major regulatory axis in the human breast. | Q51042996 | ||
| Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. | Q51054343 | ||
| Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. | Q52172979 | ||
| Breast cancer cells interact with osteoblasts to support osteoclast formation | Q73025244 | ||
| Enhanced expression and shedding of receptor activator of NF-kappaB ligand during tumor-bone interaction potentiates mammary tumor-induced osteolysis | Q84204534 | ||
| Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study | Q85448625 | ||
| Shedding of RANKL by tumor-associated MT1-MMP activates Src-dependent prostate cancer cell migration. | Q33958982 | ||
| Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice | Q34344554 | ||
| DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process | Q34596316 | ||
| Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling | Q35194008 | ||
| Canonical and non-canonical NF-κB signaling promotes breast cancer tumor-initiating cells | Q35586803 | ||
| The Role of Cancer Stem Cells in the Organ Tropism of Breast Cancer Metastasis: A Mechanistic Balance between the "Seed" and the "Soil"? | Q35684577 | ||
| CXCL13 activation of c-Myc induces RANK ligand expression in stromal/preosteoblast cells in the oral squamous cell carcinoma tumor-bone microenvironment | Q35968894 | ||
| C-Src-mediated RANKL-induced breast cancer cell migration by activation of the ERK and Akt pathway | Q35995710 | ||
| IkappaB kinase alpha kinase activity is required for self-renewal of ErbB2/Her2-transformed mammary tumor-initiating cells | Q36023768 | ||
| Integrin αvβ3 and CD44 pathways in metastatic prostate cancer cells support osteoclastogenesis via a Runx2/Smad 5/receptor activator of NF-κB ligand signaling axis | Q36402883 | ||
| Oral squamous carcinoma cells secrete RANKL directly supporting osteolytic bone loss | Q36480992 | ||
| HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. | Q36693285 | ||
| Cancer to bone: a fatal attraction | Q36884628 | ||
| RANK ligand as a therapeutic target for bone metastases and multiple myeloma | Q36983217 | ||
| Breast cancer-derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: implication for breast cancer osteolytic bone metastases | Q37066448 | ||
| ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis | Q37302910 | ||
| Epithelial plasticity, cancer stem cells and bone metastasis formation | Q37776565 | ||
| RANK expression on breast cancer cells promotes skeletal metastasis | Q39055979 | ||
| RANKL synthesized by both stromal cells and cancer cells plays a crucial role in osteoclastic bone resorption induced by oral cancer. | Q39180383 | ||
| Location matters: osteoblast and osteoclast distribution is modified by the presence and proximity to breast cancer cells in vivo | Q39352902 | ||
| RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis | Q39365550 | ||
| Dual function of ERRα in breast cancer and bone metastasis formation: implication of VEGF and osteoprotegerin | Q39511667 | ||
| RANKL expression specifically observed in vivo promotes epithelial mesenchymal transition and tumor progression | Q39544703 | ||
| Hypoxia induces RANK and RANKL expression by activating HIF-1α in breast cancer cells | Q39554339 | ||
| RANKL increases migration of human lung cancer cells through intercellular adhesion molecule-1 up-regulation | Q39590554 | ||
| Receptor activator of NF-kappaB ligand enhances breast cancer-induced osteolytic lesions through upregulation of extracellular matrix metalloproteinase inducer/CD147. | Q39680208 | ||
| Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas | Q39849289 | ||
| Involvement of cell-cell and cell-matrix interactions in bone destruction induced by metastatic MDA-MB-231 human breast cancer cells in nude mice | Q39922305 | ||
| Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone | Q39946634 | ||
| 17beta-Estradiol inhibits osteoprotegerin production by the estrogen receptor-alpha-positive human breast cancer cell line MCF-7. | Q40016291 | ||
| Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis | Q40038407 | ||
| RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes | Q40050213 | ||
| Bone metastasis: can osteoclasts be excluded? | Q40168326 | ||
| Regulation of cancer cell migration and bone metastasis by RANKL. | Q40298349 | ||
| Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial | Q41489196 | ||
| Epithelial to mesenchymal transition (EMT) in human prostate cancer: lessons learned from ARCaP model | Q41902936 | ||
| Constitutive activation of RANK disrupts mammary cell fate leading to tumorigenesis. | Q42439949 | ||
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 519 | |
| P577 | publication date | 2014-01-01 | |
| P1433 | published in | BoneKEy reports | Q27724456 |
| P1476 | title | Targeting RANKL in metastasis | |
| P478 | volume | 3 |
| Q49913672 | AR Expression in Breast Cancer CTCs Associates with Bone Metastases. |
| Q50091360 | Autoregulation of RANK Ligand in Oral Squamous Cell Carcinoma Tumor Cells. |
| Q34366449 | Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond |
| Q94355689 | Bisphosphonates or RANK‐ligand‐inhibitors for men with prostate cancer and bone metastases: a Cochrane Review and network meta‐analysis |
| Q28081996 | Bone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myeloma |
| Q38787494 | Bone remodeling and regulating biomarkers in women at the time of breast cancer diagnosis |
| Q35780792 | Bone-targeted agents in the treatment of lung cancer. |
| Q42135817 | Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions. |
| Q34325491 | Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases |
| Q56961932 | Harnessing the potential of therapeutic agents to safeguard bone health in prostate cancer |
| Q37295749 | High fat diet increases melanoma cell growth in the bone marrow by inducing osteopontin and interleukin 6 |
| Q28077444 | Implications of Hypoxia in Breast Cancer Metastasis to Bone |
| Q48147981 | Interplay between low plasma RANKL and VDR-FokI polymorphism in lumbar disc herniation independently from age, body mass, and environmental factors: a case-control study in the Italian population. |
| Q36426121 | Isoliquiritigenin Inhibits Metastatic Breast Cancer Cell-induced Receptor Activator of Nuclear Factor Kappa-B Ligand/Osteoprotegerin Ratio in Human Osteoblastic Cells. |
| Q42508259 | Metformin inhibits RANKL and sensitizes cancer stem cells to denosumab |
| Q33631557 | Minireview: Progesterone Regulation of Proliferation in the Normal Human Breast and in Breast Cancer: A Tale of Two Scenarios? |
| Q98465934 | Molecular mechanisms and clinical management of cancer bone metastasis |
| Q52315473 | NF-κB, the Importance of Being Dynamic: Role and Insights in Cancer. |
| Q48194383 | Pathologic conditions of hard tissue: role of osteoclasts in osteolytic lesion |
| Q28066865 | Progression and metastasis of lung cancer |
| Q37179783 | RANK and RANK ligand expression in primary human osteosarcoma |
| Q56892940 | RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer |
| Q60917149 | RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives |
| Q91253715 | Receptor activator of NF-κB (RANK)-mediated induction of metastatic spread and association with poor prognosis in renal cell carcinoma |
| Q60489259 | Roles of the RANKL–RANK axis in antitumour immunity — implications for therapy |
| Q92602305 | Sex-determining region Y (SRY) attributes to gender differences in RANKL expression and incidence of osteoporosis |
| Q36067243 | Targeting stem cell niche can protect hematopoietic stem cells from chemotherapy and G-CSF treatment |
| Q28070036 | The Janus Face of Death Receptor Signaling during Tumor Immunoediting |
| Q37269535 | Transcriptional regulation of tenascin-W by TGF-beta signaling in the bone metastatic niche of breast cancer cells |
| Q46567372 | Treatment with anti-RANKL antibody reduces infarct size and attenuates dysfunction impacting on neutrophil-mediated injury |
| Q90461397 | Up-regulated expression of CD147 gene in malignant bone tumor and the possible induction mechanism during osteoclast formation |
Search more.